By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

38 Jackson Road

Devens  Massachusetts  01434  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS



Bristol-Myers Squibb is a global biopharmaceutical company dedicated to helping patients prevail against serious disease.

We have delivered nine new products to patients in the last seven years for the treatment of psychiatric disorders, cancer, HIV, chronic hepatitis B and rheumatoid arthritis. We anticipate up to 6 additional regulatory approvals or submissions through 2012. In addition, scores of investigational medicines are advancing through our pharmaceutical development pipeline for such additional diseases as diabetes and cardiovascular disease, solid organ transplant rejection, Alzheimer's and obesity.

Bristol-Myers Squibb is recognized as having one of the most productive pipelines in the industry. Two of our marketed productive pipelines in the industry. Two of our marketed medicines and a number of investigational products are biologics. In the fight against serious disease, biologics - or protein-derived therapies - are playing an increasingly prominent role.

In our quest to help patients prevail, we are redefining our company and transforming ourselves for the future. By uniquely combining the strengths of a traditional pharmaceutical company with the attributes of a successful biotech company, we are becoming a new kind of enterprise, a next generation BioPharma. We are focused - agile and flexible, and infused with the entrepreneurial culture of an innovative biotech. Yet, at the same time, we are large enough to marshal the resources necessary to invest in our pipeline and bring new medicines to patients in need.

As a BioPharma leader, we are complementing and enhancing our internal capabilities with innovative alliances, partnerships and acquisitions. We call this our String of Pearls strategy.

Over the years, Bristol-Myers Squibb and its employees have received numerous distinguished awards and recognitions, including the National Medal of Technology and the Lasker Award for Medical Research. Recently, Bristol-Myers Squibb was included among Barron's 2009 Most Respected Companies Survey. Also, we've been hailed year after year as one of the best companies for working mothers and executive women, and as an acknowledged industry leader in environment, health, and safety management.



Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 









Company News
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) And Prevention Of Recurrent DVT And PE 11/26/2014 10:57:24 AM
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 11/26/2014 7:47:18 AM
Bristol-Myers Squibb Company (BMY) And Five Prime Therapeutics, Inc. (FPRX) Announce Exclusive Clinical Collaboration To Evaluate The Combination Of Investigational Immunotherapies Opdivo (nivolumab) And FPA008 In Six Tumor Types 11/24/2014 8:44:55 AM
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (Apixaban) 11/17/2014 10:39:26 AM
Bristol-Myers Squibb Company (BMY) To Create Up To 400 New Jobs As Part Of A $900 Million Investment 11/14/2014 6:20:32 AM
Bristol-Myers Squibb Company (BMY) To Present Sixteen Orencia (abatacept) Data Abstracts At The American College of Rheumatology 2014 Annual Meeting 11/12/2014 10:31:43 AM
Multiple Bristol-Myers Squibb Company (BMY) Oncology Compounds To Be Featured In Oral Presentations At 56th Annual American Society of Hematology Meeting 11/10/2014 10:05:56 AM
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Competing Hodgkin’s Drugs Look Comparable, Says Analyst 11/6/2014 2:53:07 PM
Bristol-Myers Squibb Company (BMY) Forges $475 Million Pact For Rights To f-Star's Cancer Drug 10/28/2014 5:57:19 AM
Bristol-Myers Squibb Company (BMY) Reports Third Quarter 2014 Financial Results 10/24/2014 9:37:22 AM
12345678910...
//-->